Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Monique A. Franc"'
Autor:
Chih Cherng Lu, Joris Vandenbossche, Stephan Francke, Henry M Richards, An Van den Bergh, Monique A. Franc
Publikováno v:
The Journal of Clinical Pharmacology. 54:1170-1179
This open-label, single-center, phase I study (NCT1487564) investigated the effect of uridine diphosphate-glucuronosyltransferase2B7 (UGT2B7 * 2) genetic polymorphism (H268Y) on the pharmacokinetics (PK) and safety of a single, oral, 16-mg dose of OR
Autor:
Juergen Brinkmeyer, Juergen Gallinat, Monique A. Franc, Dan Rujescu, Maarten Timmers, Yu Sun, Sivi Ouwerkerk-Mahadevan, Johannes Streffer, Georg Winterer, Luc Janssens, Francesco Musso, Johannes Kornhuber, Reyna Favis, Norbert Thuerauf
Publikováno v:
Neuropharmacology. 64:197-204
In this multicenter, double-blind, placebo-controlled, randomized, four way cross-over proof-of-mechanism study, we tested the effect of the positive allosteric α7 nicotinic acetylcholine receptor (nAChR) modulator JNJ-39393406 in a key translationa
Autor:
Monique A. Franc, Ekopimo Ibia, Scott D. Patterson, Brian B Spear, Eileen Emison, William Brian, Rizwana Sproule, Michael R Bristow, Anahita Bhathena, Nadine Cohen, Chris B. Russell, Maha Karnoub, Amelia Wall Warner, Dai Wang, Peter M. Shaw, Diane M. Barnes, Shirin Khambata-Ford, Peggy H. Wong, Amir Snapir, Sharada Louis Truter, Agnes Westelinck
Publikováno v:
Pharmacogenomics. 12:939-951
One approach to delivering cost-effective healthcare requires the identification of patients as individuals or subpopulations that are more likely to respond to an appropriate dose and/or schedule of a therapeutic agent, or as subpopulations that are
Publikováno v:
Clinical Pharmacology & Therapeutics. 89:546-553
Collection and storage of DNA samples in clinical drug development programs are an important investment for the pharmaceutical industry to allow efficient evaluation of observed variability in drug response. To enable collection and future use of sam
Autor:
Juan Jose Perez-Ruixo, Monique A. Franc, Stephan Francke, Vladimir Piotrovsky, Peter Zannikos, Vural Ozdemir
Publikováno v:
Cancer Chemotherapy and Pharmacology. 58:681-691
Objective: Evaluate the effect of CYP2D6 genotype on the pharmacokinetics of tipifarnib. Methods: A total of 268 subjects included in six clinical trials were treated orally with tablet formulation of tipifarnib, as a single dose or as multiple b.i.d
Autor:
Raimo Pohjanvirta, Jouko Tuomisto, Paul C. Boutros, Nathalie Tijet, Ivy D. Moffat, Allan B. Okey, Merja Korkalainen, Monique A. Franc
Publikováno v:
Toxicology and Applied Pharmacology. 207:43-51
Mechanistic toxicology has predominantly been focused on adverse effects that are caused by reactive metabolites or by reactive oxygen species. However, many important xenobiotics exert their toxicity, not by generating reactive products, but rather
Publikováno v:
Biochemical Pharmacology. 62:1565-1578
The aryl hydrocarbon receptor (AHR) mediates toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and regulates expression of several genes such as CYP1A1. Little is known about what regulates expression of the AHR itself. We tested the ability of
Autor:
Joanna M. Karasinska, John V. Giannone, Patricia A. Harper, Monique A. Franc, Jouni T. Tuomisto, Matti Viluksela, Raimo Pohjanvirta, Mary Holowenko, Mikko Unkila, Allan B. Okey, Jouko Tuomisto
Publikováno v:
Toxicology and Applied Pharmacology. 155:82-95
Long-Evans rats (strain Turku AB; L-E) are at least 1000-fold more sensitive (LD50 about 10 microg/kg) to the acute lethal effects of 2, 3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) than are Han/Wistar (Kuopio; H/W) rats (LD509600 microg/kg). The AH rece
Autor:
Dai Wang, Catalina Lopez-Correa, N Grecco, Lois Hinman, Monique A. Franc, Amir Snapir, S P Piccoli, Amelia Wall Warner, Nadine Cohen, Sharada Louis Truter, Agnes Westelinck
Publikováno v:
Clinical pharmacology and therapeutics. 91(6)
Interindividual variation in pharmacodynamic (PD) response to drugs is an ongoing area of research for drugs in clinical development, pre- and postapproval. To characterize how pharmacogenomic (PG) variations can serve as a predictor of differences i
Publikováno v:
Clinical pharmacology and therapeutics. 89(4)
DNA samples collected in clinical trials and stored for future research are valuable to pharmaceutical drug development. Given the perceived higher risk associated with genetic research, industry has implemented complex coding methods for DNA. Follow